Analysts Anticipate Acorda Therapeutics Inc (NASDAQ:ACOR) Will Announce Quarterly Sales of $36.90 Million

Brokerages forecast that Acorda Therapeutics Inc (NASDAQ:ACOR) will post sales of $36.90 million for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Acorda Therapeutics’ earnings, with the lowest sales estimate coming in at $27.26 million and the highest estimate coming in at $43.80 million. Acorda Therapeutics reported sales of $69.15 million in the same quarter last year, which would suggest a negative year over year growth rate of 46.6%. The business is expected to announce its next quarterly earnings report on Thursday, February 13th.

According to Zacks, analysts expect that Acorda Therapeutics will report full year sales of $177.32 million for the current financial year, with estimates ranging from $163.95 million to $185.70 million. For the next financial year, analysts anticipate that the business will post sales of $146.14 million, with estimates ranging from $64.22 million to $212.00 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Acorda Therapeutics.

Acorda Therapeutics (NASDAQ:ACOR) last released its quarterly earnings data on Monday, November 4th. The biopharmaceutical company reported ($0.46) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.51) by $0.05. The company had revenue of $47.72 million during the quarter, compared to the consensus estimate of $43.23 million. Acorda Therapeutics had a negative return on equity of 12.96% and a negative net margin of 155.89%. The firm’s revenue was down 66.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.17 earnings per share.

Several brokerages have weighed in on ACOR. JPMorgan Chase & Co. cut Acorda Therapeutics from a “neutral” rating to an “underweight” rating and set a $1.40 price objective on the stock. in a research note on Thursday, October 24th. ValuEngine lowered Acorda Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. HC Wainwright reaffirmed a “hold” rating and set a $6.00 target price on shares of Acorda Therapeutics in a research report on Tuesday. Stifel Nicolaus decreased their target price on Acorda Therapeutics from $12.00 to $7.00 and set a “hold” rating for the company in a research report on Friday, August 2nd. Finally, Cantor Fitzgerald decreased their price objective on Acorda Therapeutics from $20.00 to $12.00 and set a “neutral” rating for the company in a report on Friday, August 2nd. Four research analysts have rated the stock with a sell rating, six have given a hold rating and two have issued a buy rating to the company. Acorda Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $11.07.

NASDAQ:ACOR traded down $0.07 on Monday, reaching $2.34. 1,754,000 shares of the stock traded hands, compared to its average volume of 1,241,972. Acorda Therapeutics has a 1-year low of $1.58 and a 1-year high of $21.13. The company’s 50 day moving average is $2.57 and its 200-day moving average is $5.87. The company has a current ratio of 3.42, a quick ratio of 3.52 and a debt-to-equity ratio of 1.33. The firm has a market capitalization of $114.50 million, a price-to-earnings ratio of 1.29 and a beta of 1.18.

A number of hedge funds have recently bought and sold shares of the business. Advisory Services Network LLC grew its stake in Acorda Therapeutics by 9.6% in the second quarter. Advisory Services Network LLC now owns 40,000 shares of the biopharmaceutical company’s stock worth $307,000 after purchasing an additional 3,500 shares during the period. Aperio Group LLC grew its stake in Acorda Therapeutics by 39.0% in the second quarter. Aperio Group LLC now owns 14,124 shares of the biopharmaceutical company’s stock worth $108,000 after purchasing an additional 3,961 shares during the period. KBC Group NV purchased a new stake in Acorda Therapeutics in the second quarter worth $31,000. Comerica Bank grew its stake in Acorda Therapeutics by 22.5% in the third quarter. Comerica Bank now owns 44,988 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 8,268 shares during the period. Finally, Gabelli Funds LLC purchased a new stake in Acorda Therapeutics in the second quarter worth $80,000.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Selincro, an orally administered drug for the treatment of alcohol dependence in Europe.

Further Reading: Cost of Equity For A Business, Investors

Get a free copy of the Zacks research report on Acorda Therapeutics (ACOR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.